Jian-song Q. Ji

289 Kuocang Road, 32300
Lishui, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 52 publications

Transarterial Chemoembolization Combined With Camrelizumab and Rivoceranib for Unresectable Hepatocellular Carcinoma (CHANCE2005/CARES-005): A Randomized Phase II Trial.

Transarterial Chemoembolization Combined With Camrelizumab and Rivoceranib for Unresectable Hepatocellular Carcinoma (CHANCE2005/CARES-005): A Randomized Phase II Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: February 24, 2026

Camrelizumab and Apatinib With or Without Transarterial Chemoembolisation as First-Line Treatment for Advanced Hepatocellular Carcinoma.

Camrelizumab and Apatinib With or Without Transarterial Chemoembolisation as First-Line Treatment for Advanced Hepatocellular Carcinoma.

Journal: Alimentary pharmacology & therapeutics

Published: December 10, 2025

Should transarterial chemoembolization be applied with systemic therapy for hepatocellular carcinoma with hepatic vein and/or inferior vena cava tumor thrombus (CHANCE2505)?: a multicenter study.

Should transarterial chemoembolization be applied with systemic therapy for hepatocellular carcinoma with hepatic vein and/or inferior vena cava tumor thrombus (CHANCE2505)?: a multicenter study.

Journal: International journal of surgery (London, England)

Published: September 16, 2025

Transarterial chemoembolization (TACE) combined with immunotherapy and anti-angiogenic agents in intermediate-stage hepatocellular carcinoma (CHANCE2202): a target trial emulation study.

Transarterial chemoembolization (TACE) combined with immunotherapy and anti-angiogenic agents in intermediate-stage hepatocellular carcinoma (CHANCE2202): a target trial emulation study.

Journal: EClinicalMedicine

Published: September 14, 2025

The METAL Score for Early Stratification of Radiological Response and Survival in Hepatocellular Carcinoma Treated with TACE and Immunotherapy Combinations.

The METAL Score for Early Stratification of Radiological Response and Survival in Hepatocellular Carcinoma Treated with TACE and Immunotherapy Combinations.

Journal: Academic radiology

Published: September 12, 2025

Decoding tumor heterogeneity with imaging biomarkers predicts response to TACE plus immunotherapy and targeted therapy in HCC (CHANCE2204).

Decoding tumor heterogeneity with imaging biomarkers predicts response to TACE plus immunotherapy and targeted therapy in HCC (CHANCE2204).

Journal: Hepatology (Baltimore, Md.)

Published: July 13, 2025

Adefovir dipivoxil-induced Fanconi syndrome associated with hypophosphatemic osteomalacia misdiagnosed as cervical spondylotic myelopathy: A case report and literature review.

Adefovir dipivoxil-induced Fanconi syndrome associated with hypophosphatemic osteomalacia misdiagnosed as cervical spondylotic myelopathy: A case report and literature review.

Journal: Medicine

Published: June 14, 2025

125I stent plus combination therapy for HCC and portal vein tumor thrombosis: a nationwide target trial emulation.

125I stent plus combination therapy for HCC and portal vein tumor thrombosis: a nationwide target trial emulation.

Journal: International journal of surgery (London, England)

Published: June 03, 2025

Self-Illuminating Nanoagonist Simultaneously Induces Dual Cell Death Pathways via Death Receptor Clustering for Cancer Therapy.

Self-Illuminating Nanoagonist Simultaneously Induces Dual Cell Death Pathways via Death Receptor Clustering for Cancer Therapy.

Journal: ACS nano

Published: June 24, 2024

Multiple Immunomodulatory Strategies Based on Targeted Regulation of Proprotein Convertase Subtilisin/Kexin Type 9 and Immune Homeostasis against Hepatocellular Carcinoma.

Multiple Immunomodulatory Strategies Based on Targeted Regulation of Proprotein Convertase Subtilisin/Kexin Type 9 and Immune Homeostasis against Hepatocellular Carcinoma.

Journal: ACS nano

Published: March 11, 2024

Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study.

Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study.

Journal: EClinicalMedicine

Published: January 10, 2024

Gastroenteropancreatic neuroendocrine neoplasms: current development, challenges, and clinical perspectives.

Gastroenteropancreatic neuroendocrine neoplasms: current development, challenges, and clinical perspectives.

Journal: Military Medical Research

Published: June 11, 2023

Showing 1-12 of 52

Last Updated: 09/26/2026